- Home
- GILD vs MELI Comparison
GILD vs MELI Comparison
Compare GILD & MELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MELI
- Stock Information
- Founded
- GILD 1987
- MELI 1999
- Country
- GILD United States
- MELI Uruguay
- Employees
- GILD N/A
- MELI N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MELI Catalog/Specialty Distribution
- Sector
- GILD Health Care
- MELI Consumer Discretionary
- Exchange
- GILD Nasdaq
- MELI Nasdaq
- Market Cap
- GILD 138.7B
- MELI 124.4B
- IPO Year
- GILD 1992
- MELI 2007
- Fundamental
- Price
- GILD $110.17
- MELI $2,394.26
- Analyst Decision
- GILD Buy
- MELI Strong Buy
- Analyst Count
- GILD 24
- MELI 16
- Target Price
- GILD $110.95
- MELI $2,617.81
- AVG Volume (30 Days)
- GILD 6.3M
- MELI 305.8K
- Earning Date
- GILD 08-07-2025
- MELI 07-31-2025
- Dividend Yield
- GILD 2.87%
- MELI N/A
- EPS Growth
- GILD 1118.07
- MELI 82.40
- EPS
- GILD 4.73
- MELI 40.65
- Revenue
- GILD $28,735,000,000.00
- MELI $22,379,000,000.00
- Revenue This Year
- GILD $1.69
- MELI $34.37
- Revenue Next Year
- GILD $3.67
- MELI $24.88
- P/E Ratio
- GILD $23.29
- MELI $58.66
- Revenue Growth
- GILD 4.68
- MELI 37.68
- 52 Week Low
- GILD $70.78
- MELI $1,579.78
- 52 Week High
- GILD $119.96
- MELI $2,645.22
- Technical
- Relative Strength Index (RSI)
- GILD 51.17
- MELI 45.38
- Support Level
- GILD $107.75
- MELI $2,345.00
- Resistance Level
- GILD $110.90
- MELI $2,428.04
- Average True Range (ATR)
- GILD 2.31
- MELI 56.81
- MACD
- GILD -0.38
- MELI -9.49
- Stochastic Oscillator
- GILD 33.99
- MELI 28.14
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MELI MercadoLibre Inc.
MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.